CSTL Castle Biosciences

Castle Biosciences Added to NASDAQ Biotechnology Index

FRIENDSWOOD, Texas--(BUSINESS WIRE)--

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is evaluated semi-annually in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB).

This is the most recent index to which Castle Biosciences has been added in 2019. The Company is also included in the US small-cap Russell 2000® Index.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; ) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq; ), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

EN
18/12/2019

Underlying

CSTLCastle Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

February 5, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.12
NUE Nucor Corporati...
PKG Packaging Corpo... ... (+35)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

NUE NUCOR CORPORATION
PKG PACKAGING CORPORATION OF AMERICA
SCCO SOUTHERN COPPER CORPORATION
PAA PLAINS ALL AMERICAN PIPELINE L.P.
LXU LSB INDUSTRIES INC.
LNTH LANTHEUS HOLDINGS INC
KMB KIMBERLY-CLARK CORPORATION
JYNT JOINT CORP
HUBB HUBBELL INCORPORATED CLASS B
HRL HORMEL FOODS CORPORATION
GPRK GEOPARK
DAN DANA INCORPORATED
CVS CVS HEALTH CORPORATION
BLL BALL CORPORATION
ASH ASHLAND GLOBAL HOLDINGS INC.
ACD ADECOAGRO S.A.
ADM ARCHER-DANIELS-MIDLAND COMPANY
NYT NEW YORK TIMES COMPANY CLASS A
ATRO ASTRONICS CORPORATION
DRI DARDEN RESTAURANTS INC.
SXC SUNCOKE ENERGY INC.
CDZI CADIZ INC.
TEC TECHNIPFMC PLC
RNGR RANGER ENERGY SERVICES
CSTL CASTLE BIOSCIENCES
APA APA CORPORATION
AKLCP ONTO INNOVATION INC.
PR KOLTSOVO AIRPORT
BG PERMIAN RESOURCES CORPORATION
PRMB BUNGE LIMITED
USAU PRIMO BRANDS CORP
UAN US GOLD CORP
DFTX ARCADIAN PARTNERS LP PFD
VXX DEFINIUM THERAPEUTICS INC.
IPATH SERIES B S&P 500 VIX SHORT-TERM FUTURES ETN
01/27/26 January 27, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and ...

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide pati...

January 11, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

December 19, 2025 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expr...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch